Cargando…

Glutathione-sensitive nanoparticles enhance the combined therapeutic effect of checkpoint kinase 1 inhibitor and cisplatin in prostate cancer

Prostate cancer (PCa) is the second most common malignant tumor among males. Traditional treatments for PCa, which include surgery and endocrine therapy, have shown limited success, and more effective therapies are needed. Cisplatin (DDP) is an approved chemotherapeutic drug that causes DNA damage i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Shirong, Zhang, Xinyu, Huang, Hao, Cheng, Bisheng, Xiong, Zhi, Du, Tao, Wu, Jun, Huang, Hai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AIP Publishing LLC 2022
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686925/ https://www.ncbi.nlm.nih.gov/pubmed/36440378 http://dx.doi.org/10.1063/5.0126095

Ejemplares similares

Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer: targeting the androgen receptor-regulated tumor immune microenvironment
por: Cheng, Bisheng, et al.
Publicado: (2023)

Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells
por: Zhu, Jian, et al.
Publicado: (2019)

Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer
por: Gao, Ze, et al.
Publicado: (2020)

Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer
por: Chen, Yang, et al.
Publicado: (2022)

Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
por: Rocha, C R R, et al.
Publicado: (2014)

Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo
por: Rocha, C R R, et al.
Publicado: (2015)

Role of glutathione, glutathione S-transferases and multidrug resistance-related proteins in cisplatin sensitivity of head and neck cancer cell lines.
por: Welters, M. J., et al.
Publicado: (1998)

Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles
por: Xiong, Xunhao, et al.
Publicado: (2014)

Mass spectrometry imaging and monitoring of in vivo glutathione-triggered cisplatin release from nanoparticles in the kidneys
por: Chung, Arthur C. K., et al.
Publicado: (2020)

“Pincer movement”: Reversing cisplatin resistance based on simultaneous glutathione depletion and glutathione S-transferases inhibition by redox-responsive degradable organosilica hybrid nanoparticles
por: Niu, Boyi, et al.
Publicado: (2022)

NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017)

Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
por: Chen, Helen H. W., et al.
Publicado: (2010)

Elevated Glutathione Peroxidase 2 Expression Promotes Cisplatin Resistance in Lung Adenocarcinoma
por: Du, He, et al.
Publicado: (2020)

Injectable hydrogel with selenium nanoparticles delivery for sustained glutathione peroxidase activation and enhanced osteoarthritis therapeutics
por: Hu, Wenhui, et al.
Publicado: (2023)

Isoalantolactone Increases the Sensitivity of Prostate Cancer Cells to Cisplatin Treatment by Inducing Oxidative Stress
por: Huang, Hang, et al.
Publicado: (2021)

Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils
por: Zhou, Ziwei, et al.
Publicado: (2022)

Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells
por: Du, Zhen-Xian, et al.
Publicado: (2009)

Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics
por: Buss, Colin G., et al.
Publicado: (2020)

BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin
por: Bansal, Nisha, et al.
Publicado: (2012)

Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers
por: Jin, Yonglong, et al.
Publicado: (2020)

Glutathione-mediated biotransformation in the liver modulates nanoparticle transport
por: Jiang, Xingya, et al.
Publicado: (2019)

The Schizosaccharomyces pombe Checkpoint Kinases Chk1 and Cds1 Are Important for Cell Survival in Response to Cisplatin
por: Paparatto, Domenica, et al.
Publicado: (2009)

Glutathione metabolism rewiring protects renal tubule cells against cisplatin-induced apoptosis and ferroptosis
por: Dong, Xing-Qiang, et al.
Publicado: (2023)

A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer
por: Antonarakis, Emmanuel S.
Publicado: (2019)

GADD45B Is a Potential Diagnostic and Therapeutic Target Gene in Chemotherapy-Resistant Prostate Cancer
por: Wang, Qiong, et al.
Publicado: (2021)

Prostate cancer and glutathione S-transferase deletions
por: Malik, Saima Shakil, et al.
Publicado: (2015)

Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy
por: Feldmann, Daniel P., et al.
Publicado: (2020)

Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib
por: Wang, Lihong, et al.
Publicado: (2017)

Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma
por: Yang, Fen, et al.
Publicado: (2013)

The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation
por: Hongo, Hiroshi, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang, Jin-Tao, et al.
Publicado: (2022)

Bucillamine prevents cisplatin-induced ototoxicity through induction of glutathione and antioxidant genes
por: Kim, Se-Jin, et al.
Publicado: (2015)

Immune Checkpoint Inhibitors in Prostate Cancer
por: Venkatachalam, Shobi, et al.
Publicado: (2021)

Overexpression of Glutathione S-Transferases in Human Diseases: Drug Targets and Therapeutic Implications
por: Lv, Ning, et al.
Publicado: (2023)

First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis
por: Lin, Chang-Ting, et al.
Publicado: (2022)

FOLR1 increases sensitivity to cisplatin treatment in ovarian cancer cells
por: Huang, Ming-ju, et al.
Publicado: (2018)

Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade
por: Dmello, Crismita, et al.
Publicado: (2023)

Effect of cyclin-dependent kinase 7 silencing on cisplatin sensitivity in endometrial carcinoma cells
por: LIU, WEN-XIN, et al.
Publicado: (2015)

IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin
por: O'Flanagan, Ciara H., et al.
Publicado: (2016)

Oxidation of Human Copper Chaperone Atox1 and Disulfide Bond Cleavage by Cisplatin and Glutathione
por: Nardella, Maria I., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_una9cv4nlc6glq8ab72a698lsc